Cargando…

Antecedent hypertension and myocardial injury in patients with reperfused ST-elevation myocardial infarction

BACKGROUND: Antecedent hypertension is associated with poor outcome in patients with ST-elevation myocardial infarction (STEMI). Whether differences in myocardial salvage, infarct size and microvascular injury contribute to the adverse outcome is unknown. We investigated the association between ante...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinstadler, Sebastian J., Stiermaier, Thomas, Eitel, Charlotte, Saad, Mohammed, Metzler, Bernhard, de Waha, Suzanne, Fuernau, Georg, Desch, Steffen, Thiele, Holger, Eitel, Ingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5105316/
https://www.ncbi.nlm.nih.gov/pubmed/27832796
http://dx.doi.org/10.1186/s12968-016-0299-1
_version_ 1782466880889421824
author Reinstadler, Sebastian J.
Stiermaier, Thomas
Eitel, Charlotte
Saad, Mohammed
Metzler, Bernhard
de Waha, Suzanne
Fuernau, Georg
Desch, Steffen
Thiele, Holger
Eitel, Ingo
author_facet Reinstadler, Sebastian J.
Stiermaier, Thomas
Eitel, Charlotte
Saad, Mohammed
Metzler, Bernhard
de Waha, Suzanne
Fuernau, Georg
Desch, Steffen
Thiele, Holger
Eitel, Ingo
author_sort Reinstadler, Sebastian J.
collection PubMed
description BACKGROUND: Antecedent hypertension is associated with poor outcome in patients with ST-elevation myocardial infarction (STEMI). Whether differences in myocardial salvage, infarct size and microvascular injury contribute to the adverse outcome is unknown. We investigated the association between antecedent hypertension and cardiovascular magnetic resonance (CMR) parameters of myocardial salvage and damage in a multicenter CMR substudy of the AIDA-STEMI trial (Abciximab Intracoronary versus intravenously Drug Application in ST-elevation myocardial infarction). METHODS: We analyzed 792 consecutive STEMI patients reperfused within 12 h after symptom onset. Patients underwent CMR imaging for assessment of myocardial salvage, infarct size and microvascular obstruction within 10 days after infarction. Major adverse cardiac events (MACE) were recorded at 12-month follow-up. RESULTS: Antecedent hypertension was present in 540 patients (68 %) and was associated with a significantly increased baseline risk profile (advanced age, higher body mass index, higher incidence of diabetes, hypercholesterolemia, previous angioplasty and multivessel disease, p < 0.001 for all). MACE were more frequent in patients with hypertension as compared to patients without hypertension (45 [8 %] vs. 8 [3 %], p < 0.01). Antecedent hypertension remained an independent predictor of MACE after multivariate adjustment (hazard ratio 3.42 [confidence interval 1.45–8.08], p < 0.01). There was, however, no significant difference in the area at risk, infarct size, myocardial salvage index, extent of microvascular obstruction, and left ventricular ejection fraction between the groups (all p > 0.05). CONCLUSION: Despite a higher rate of MACE in contemporary reperfused STEMI patients with antecedent hypertension, there was no difference in reperfusion efficacy, infarct size and reperfusion injury as visualized by CMR. TRIAL REGISTRATION: NCT00712101.
format Online
Article
Text
id pubmed-5105316
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51053162016-11-14 Antecedent hypertension and myocardial injury in patients with reperfused ST-elevation myocardial infarction Reinstadler, Sebastian J. Stiermaier, Thomas Eitel, Charlotte Saad, Mohammed Metzler, Bernhard de Waha, Suzanne Fuernau, Georg Desch, Steffen Thiele, Holger Eitel, Ingo J Cardiovasc Magn Reson Research BACKGROUND: Antecedent hypertension is associated with poor outcome in patients with ST-elevation myocardial infarction (STEMI). Whether differences in myocardial salvage, infarct size and microvascular injury contribute to the adverse outcome is unknown. We investigated the association between antecedent hypertension and cardiovascular magnetic resonance (CMR) parameters of myocardial salvage and damage in a multicenter CMR substudy of the AIDA-STEMI trial (Abciximab Intracoronary versus intravenously Drug Application in ST-elevation myocardial infarction). METHODS: We analyzed 792 consecutive STEMI patients reperfused within 12 h after symptom onset. Patients underwent CMR imaging for assessment of myocardial salvage, infarct size and microvascular obstruction within 10 days after infarction. Major adverse cardiac events (MACE) were recorded at 12-month follow-up. RESULTS: Antecedent hypertension was present in 540 patients (68 %) and was associated with a significantly increased baseline risk profile (advanced age, higher body mass index, higher incidence of diabetes, hypercholesterolemia, previous angioplasty and multivessel disease, p < 0.001 for all). MACE were more frequent in patients with hypertension as compared to patients without hypertension (45 [8 %] vs. 8 [3 %], p < 0.01). Antecedent hypertension remained an independent predictor of MACE after multivariate adjustment (hazard ratio 3.42 [confidence interval 1.45–8.08], p < 0.01). There was, however, no significant difference in the area at risk, infarct size, myocardial salvage index, extent of microvascular obstruction, and left ventricular ejection fraction between the groups (all p > 0.05). CONCLUSION: Despite a higher rate of MACE in contemporary reperfused STEMI patients with antecedent hypertension, there was no difference in reperfusion efficacy, infarct size and reperfusion injury as visualized by CMR. TRIAL REGISTRATION: NCT00712101. BioMed Central 2016-11-11 /pmc/articles/PMC5105316/ /pubmed/27832796 http://dx.doi.org/10.1186/s12968-016-0299-1 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Reinstadler, Sebastian J.
Stiermaier, Thomas
Eitel, Charlotte
Saad, Mohammed
Metzler, Bernhard
de Waha, Suzanne
Fuernau, Georg
Desch, Steffen
Thiele, Holger
Eitel, Ingo
Antecedent hypertension and myocardial injury in patients with reperfused ST-elevation myocardial infarction
title Antecedent hypertension and myocardial injury in patients with reperfused ST-elevation myocardial infarction
title_full Antecedent hypertension and myocardial injury in patients with reperfused ST-elevation myocardial infarction
title_fullStr Antecedent hypertension and myocardial injury in patients with reperfused ST-elevation myocardial infarction
title_full_unstemmed Antecedent hypertension and myocardial injury in patients with reperfused ST-elevation myocardial infarction
title_short Antecedent hypertension and myocardial injury in patients with reperfused ST-elevation myocardial infarction
title_sort antecedent hypertension and myocardial injury in patients with reperfused st-elevation myocardial infarction
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5105316/
https://www.ncbi.nlm.nih.gov/pubmed/27832796
http://dx.doi.org/10.1186/s12968-016-0299-1
work_keys_str_mv AT reinstadlersebastianj antecedenthypertensionandmyocardialinjuryinpatientswithreperfusedstelevationmyocardialinfarction
AT stiermaierthomas antecedenthypertensionandmyocardialinjuryinpatientswithreperfusedstelevationmyocardialinfarction
AT eitelcharlotte antecedenthypertensionandmyocardialinjuryinpatientswithreperfusedstelevationmyocardialinfarction
AT saadmohammed antecedenthypertensionandmyocardialinjuryinpatientswithreperfusedstelevationmyocardialinfarction
AT metzlerbernhard antecedenthypertensionandmyocardialinjuryinpatientswithreperfusedstelevationmyocardialinfarction
AT dewahasuzanne antecedenthypertensionandmyocardialinjuryinpatientswithreperfusedstelevationmyocardialinfarction
AT fuernaugeorg antecedenthypertensionandmyocardialinjuryinpatientswithreperfusedstelevationmyocardialinfarction
AT deschsteffen antecedenthypertensionandmyocardialinjuryinpatientswithreperfusedstelevationmyocardialinfarction
AT thieleholger antecedenthypertensionandmyocardialinjuryinpatientswithreperfusedstelevationmyocardialinfarction
AT eitelingo antecedenthypertensionandmyocardialinjuryinpatientswithreperfusedstelevationmyocardialinfarction